FCP

FCP RECOGNIZED BY FREDDIE MAC AS 2024 MULTIFAMILY IMPACT SPONSOR

Retrieved on: 
Tuesday, April 2, 2024
Partnership, ESG, FCP, Freddie Mac, Housing, Social responsibility

CHEVY CHASE, Md., April 2, 2024 /PRNewswire/ -- FCP® announces its recognition by Freddie Mac as a 2024 Multifamily Impact Sponsor .

Key Points: 
  • CHEVY CHASE, Md., April 2, 2024 /PRNewswire/ -- FCP® announces its recognition by Freddie Mac as a 2024 Multifamily Impact Sponsor .
  • The Impact Sponsor cohort comprises sponsors who have shown significant results in providing affordable housing options, offering resident-centered services, and/or implementing sustainability practices at their properties.
  • "FCP values its partnership with Freddie Mac and is honored to be recognized by them as a 2024 Multifamily Impact Sponsor, the highest level of recognition for Freddie Mac borrowers," said FCP Senior Vice President, Elizabeth Cotter.
  • FCP focuses on value-creating initiatives through resident services and utility savings projects and seeks opportunities to build resiliency while supporting the livelihoods of its residents and tenants.

C-Path Launches Clinical Trial Simulator for Duchenne Muscular Dystrophy Research

Retrieved on: 
Thursday, March 28, 2024
Research, Vital capacity, Atrophy, Disease, Data analysis, Letter, Pharming, Female, European Medicines Agency, Duchenne muscular dystrophy, Clinical trial, Drug development, FCP, FDA, DMD, CTS, Food, Pharmaceutical industry

This pioneering Drug Development Tool is set to positively impact the medical research community by significantly optimizing clinical trial design.

Key Points: 
  • This pioneering Drug Development Tool is set to positively impact the medical research community by significantly optimizing clinical trial design.
  • This Clinical Trial Simulator will positively impact DMD research by significantly optimizing clinical trial design.
  • "The launch of the DMD Clinical Trial Simulator represents a significant step forward in our fight against Duchenne muscular dystrophy," said Ramona Belfiore-Oshan, Ph.D., Executive Director for D-RSC.
  • Granting access to the D-RSC Clinical Trial Simulator through RDCA-DAP creates a unique opportunity for innovative trial designs in DMD," said Alexandre Bétourné, Pharm.D., Ph.D., Executive Director, RDCA-DAP.

Welcome a New Age of Seamless and Professional Charging with the Baseus Blade2 Ultra-Thin Laptop Power Bank

Retrieved on: 
Monday, March 11, 2024
Lithium, Carbon, Temperature, EV, QC, MSRP, Amazon, Environment, PD, Intelligence, MacBook, Travel, Electronics, Life, Silicon, Engineering, SCP, Safety, CES, FCP, AFC, Mobile phone

Lightweight and Modular Design: A key feature of the Blade2 Ultra-Thin Laptop Power Bank is its impressively flat and weightless design.

Key Points: 
  • Lightweight and Modular Design: A key feature of the Blade2 Ultra-Thin Laptop Power Bank is its impressively flat and weightless design.
  • Compatibility Across Devices: Enjoy seamless charging across multiple different devices with the Baseus Blade2 Ultra-Thin Laptop Power Bank and recharge laptops, cell phones, game consoles, headphones, and more.
  • Baseus strives to reduce the carbon footprint left behind by producing advanced technologies, such as the Blade2 Ultra-Thin Laptop Power Bank, using eco-friendly materials.
  • The Blade2 Ultra-Thin Laptop Power Bank was created to match devices in both aesthetics and performance by providing seamless and unparalleled charging, performance, and convenience.

Labroots Announces Agenda for its 7th Annual Drug Discovery & Development Virtual Event on February 21, 2024

Retrieved on: 
Thursday, February 15, 2024
Neuroscience, Toxicity, Doctor of Philosophy, FCCP, Lactation, FCP, Spectrum, Fear, Labroots, Associate, Anxiety, Networking hardware, Oxytocin, G protein-coupled receptor, Tumor microenvironment, QIAGEN, Drug discovery, Therapy, Digital image, DSM-IV codes, Thermo Fisher Scientific, Advantage Business Media, Laboratory, Miltenyi Biotec, Doctor of Pharmacy, MPS, Safety, Biomarker, Beta-lactam, Sartorius, Regulation, Master of Science, Merck, Epithelial–mesenchymal transition, Dean (education), Lung cancer, Cancer, Pharmaceutical industry

YORBA LINDA, Calif., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual event in the Drug Discovery & Development Virtual Event Series. Hosted on February 21st and free to attend, attendees will experience the forefront of pharmaceutical innovation joining industry and academic leaders from around the world debating the latest, insightful scientific breakthroughs in this ever-evolving field.

Key Points: 
  • Focusing from pre-clinical development to clinical development, advances in the field of drug discovery and development will be explored shaping current and future challenges in drug research
    YORBA LINDA, Calif., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual event in the Drug Discovery & Development Virtual Event Series .
  • The 2024 informative agenda covers a range of sessions spanning areas including Emerging Modalities in Drug Discovery and Preclinical Development, New Methods in Pharmacogenomics, and Biomarker Applications.
  • Use the hashtag #LRdrug to follow the conversation and connect with other members of the global Drug Discovery & Development community!
  • Follow @DrugDiscoveryLR on Twitter and @DrugDiscoveryandDevelopment on Facebook to connect with our specialist Drug Discovery & Development writers and stay up to date with the latest Trending News in Drug Discovery & Development.

Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness

Retrieved on: 
Wednesday, February 14, 2024
Infectious Diseases, FDA, Genetics, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Oncology, HBV, University College London, FRCS, Toxicology, Precision BioSciences, Gene editing, MD, Food, HBsAg, Precision, Feedback, CccDNA, FCP, Patient, IND, Trial of the century, CTA

Receipt of this regulatory feedback provides alignment and clarity on Precision’s final IND/CTA-enabling preclinical plans and clinical strategy for PBGENE-HBV prior to advancement into Phase 1 clinical studies.

Key Points: 
  • Receipt of this regulatory feedback provides alignment and clarity on Precision’s final IND/CTA-enabling preclinical plans and clinical strategy for PBGENE-HBV prior to advancement into Phase 1 clinical studies.
  • “Based on this feedback, we have initiated the final preclinical studies as well as site selection efforts as we move towards clinical readiness.
  • The pre-IND meeting with FDA provided feedback on overall design for the proposed first-in-human clinical study as well as feedback on the toxicology and specificity assessments.
  • “Given the constructive feedback from the FDA and other regulatory agencies worldwide, I look forward to seeing this novel modality progressing to further assessment in the clinic.”

FCP Unveils Innovative Modular Prefabricated Suspended Steel Canopy System for Industrial Building Applications

Retrieved on: 
Thursday, February 8, 2024
Rain, FCP, Architecture, Snow, Steel, Prefabrication

VENTURA, Calif., Feb. 8, 2024 /PRNewswire-PRWeb/ -- FCP Canopies, a division of FCP Inc., known for their innovation in steel fabrication, is excited to announce their modular Suspended Steel Canopy system. Its prefabricated design specifically addresses the construction industry's need for a ready-to-ship, fast installation, suspended steel canopy product for commercial and industrial building applications.

Key Points: 
  • FCP's modular Suspended Steel Canopy system is revolutionizing the way in which industrial building canopies are built.
  • VENTURA, Calif., Feb. 8, 2024 /PRNewswire-PRWeb/ -- FCP Canopies , a division of FCP Inc ., known for their innovation in steel fabrication, is excited to announce their modular Suspended Steel Canopy system.
  • Its prefabricated design specifically addresses the construction industry's need for a ready-to-ship, fast installation, suspended steel canopy product for commercial and industrial building applications.
  • However, with the introduction of FCP's modular suspended steel canopy system, this game-changing development has revolutionized the way in which canopies are built.

Critical Path Institute Appoints Dr. Klaus Romero as New CEO and Promotes Cécile Ollivier to Vice President of Global Affairs

Retrieved on: 
Thursday, January 25, 2024
FCP, European Medicines Agency, Critical Path Institute, Global health, Global Affairs Canada, EMA, Conference, Drug development, Clinical pharmacology, ICH, Pharmacology

AMSTERDAM, Jan. 25, 2024 /PRNewswire/ -- Critical Path Institute (C-Path) has named Klaus Romero, M.D., M.S., FCP, as its new Chief Executive Officer and promoted Cécile Ollivier, M.S., from Managing Director, Europe to Vice President of Global Affairs.

Key Points: 
  • AMSTERDAM, Jan. 25, 2024 /PRNewswire/ -- Critical Path Institute (C-Path) has named Klaus Romero, M.D., M.S., FCP, as its new Chief Executive Officer and promoted Cécile Ollivier, M.S., from Managing Director, Europe to Vice President of Global Affairs.
  • We are confident in his capacity to propel the organization forward in its next phase of global impact and pioneering innovation."
  • "Assuming the position of CEO at C-Path represents a profound honor, coupled with a tremendous sense of responsibility," said Romero.
  • "We are thrilled to announce the promotion of Cécile Ollivier to Vice President of Global Affairs," said C-Path Board member Tomas Salmonson Ph.D., M.S.

FCP CLOSES $11.1 MILLION IN PREFERRED EQUITY FOR 216-UNIT FLORIDA MULTIFAMILY DEVELOPMENT

Retrieved on: 
Monday, January 22, 2024
Investment, MSP, FCP

CHEVY CHASE, Md., Jan. 22, 2024 /PRNewswire/ -- FCP® announces $11.1 million in preferred equity has been invested through its Structured Investments platform to finance 1000 Jacaranda, a 216-unit, four-story, multifamily development in Venice, FL with Middle Street Partners (MSP).

Key Points: 
  • CHEVY CHASE, Md., Jan. 22, 2024 /PRNewswire/ -- FCP® announces $11.1 million in preferred equity has been invested through its Structured Investments platform to finance 1000 Jacaranda, a 216-unit, four-story, multifamily development in Venice, FL with Middle Street Partners (MSP).
  • "FCP is excited to invest with Middle Street Partners in 1000 Jacaranda," said FCP's Bruce Gago, who leads the firm's Florida office.
  • "The transaction demonstrates our ability to continue to expand our structured investments platform despite a challenging macroeconomic environment, while affirming our thesis of targeting high-growth locations with great sponsors like MSP."
  • FCP's Structured Investments platform has invested approximately $687 million of capital to date, providing flexibility and creative capital solutions to owners and developers.

C-Path Appoints Dr. Klaus Romero as New CEO

Retrieved on: 
Tuesday, January 9, 2024
Arizona State University, Patient, Therapy, FCP, Associate, CSO, Critical Path Institute, Tuberculosis, University, Society, MBA, Polycystic kidney disease, Alzheimer's disease, Disease, Drug development, Clinical pharmacology, MPH, Duchenne muscular dystrophy, International Society, Parkinson's disease, American College, Pharmacology, Kidney transplantation, Pharmaceutical industry

TUCSON, Ariz., Jan. 9, 2024 /PRNewswire/ -- Critical Path Institute (C-Path) today announced that Klaus Romero, M.D., M.S., FCP, has been named its new Chief Executive Officer. Romero, a seasoned clinician scientist, has been vital in positioning C-Path as an essential partner in accelerating drug development worldwide, significantly shaping scientific and regulatory pathways to expedite the delivery of therapies for people in urgent need.

Key Points: 
  • TUCSON, Ariz., Jan. 9, 2024 /PRNewswire/ -- Critical Path Institute (C-Path) today announced that Klaus Romero, M.D., M.S., FCP, has been named its new Chief Executive Officer.
  • "Assuming the position of CEO at C-Path represents a profound honor, coupled with a tremendous sense of responsibility," said Romero.
  • His ascension to CEO is a significant milestone in our mission to bring transformative therapies to patients who desperately need them."
  • Romero will continue to serve a dual role as CEO and CSO until the CSO position is filled.

Dr. John N. van den Anker Named New Editor-in-Chief of The Journal of Clinical Pharmacology

Retrieved on: 
Thursday, January 4, 2024
Doctor of Pharmacy, FCP, Child, JCP, Publishing, MD, Doctor of Philosophy, ACCP, Children's National Hospital, FAAP, American College, Journal, Pharmacology, Nursing

ASHBURN, Va., Jan. 4, 2024 /PRNewswire/ -- The American College of Clinical Pharmacology® (ACCP) proudly announces the appointment of Dr. John N. van den Anker, MD, PhD, FAAP, FCP, as the new Editor-in-Chief of The Journal of Clinical Pharmacology (JCP).

Key Points: 
  • ASHBURN, Va., Jan. 4, 2024 /PRNewswire/ -- The American College of Clinical Pharmacology® (ACCP) proudly announces the appointment of Dr. John N. van den Anker, MD, PhD, FAAP, FCP, as the new Editor-in-Chief of The Journal of Clinical Pharmacology (JCP).
  • A distinguished neonatal and pediatric clinical pharmacologist, Dr. van den Anker currently holds the Evan and Cindy Jones Endowed Chair of Pediatric Clinical Pharmacology at Children's National Hospital in Washington, DC.
  • With a decade of service on the JCP Editorial Board and an extensive record of publishing, Dr. van den Anker brings unparalleled expertise to his new role.
  • ACCP invites members and the scientific community to welcome Dr. John N. van den Anker and his team, marking a pivotal moment in the ongoing success of The Journal of Clinical Pharmacology.